Luigi Spadafora

MD, MSc, FISC. Cardiologist at Ospedale Santa Maria Goretti, Latina. PhD Candidate @SapienzaRoma. Associate Editor at @JCVPOnline and Cardio-Oncology.

[Michele Golino @micheleg1390]

Our last research is out!
Across 107,126 cancer patients, SGLT2i were associated with ↓ all-cause mortality, ↓ HF events, and ↓ AF/flutter. No major safety concerns.

Now let’s get the RCTs. @LuigiSpadafora @MarcoBernardiMD @gianmarcosarto @totocarbone @AbbateAntonio

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Do mineralocorticoid receptor antagonists influence circadian blood pressure patterns in hypertension?
Join the conversation 👇

https://t.co/pMVgoLRlCr
#CardioTwitter #Hypertension #CircadianRhythm #Pharmacology #CardiovascularResearch

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Should ACE inhibitors become standard prophylaxis to protect the heart during anthracycline chemotherapy?
Share your insights 👇

https://t.co/IcBHe0bmlE
#CardioTwitter #CardioOncology #Anthracyclines #HeartFailure #ClinicalResearch

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Can somatostatin analogues help reduce the need for invasive interventions in post-CABG chylothorax?
Join the discussion 👇

https://t.co/FiA57sdLAD
@EduCaitorPharmD
#CardioTwitter #CardiacSurgery #CABG #Pharmacology #ClinicalResearch

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Could targeting angiopoietin-like proteins redefine how we prevent and treat coronary heart disease?

Share your thoughts 👇

https://t.co/F4WOUistdb
#CardioTwitter #CoronaryHeartDisease #LipidMetabolism #Atherosclerosis #PrecisionMedicine

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Are oral PCSK9 inhibitors the missing link between potent LDL-C lowering and real-world accessibility?
https://t.co/kQsRYvhHvQ

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Should protamine be routine—or selective—when managing coronary perforation during CTO PCI?
https://t.co/QhyPwfOEeU
@LAzzaliniMD @DrBillLombardi @KateKearney4 @Sant_J_Kumar

#CardioTwitter #InterventionalCardiology #CTOPCI #PatientSafety #RealWorldEvidence

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Could the S-enantiomer of amlodipine offer better long-term cardiovascular protection than standard racemic amlodipine in patients with hypertension?
https://t.co/qYgG0RN92d
#CardioTwitter #Hypertension #CardiovascularOutcomes #Pharmacology #RealWorldEvidence

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Can PCSK9 inhibitors finally close the therapeutic gap for Lp(a)-driven cardiovascular risk?
https://t.co/pQDmiGt8fH
#CardioTwitter #LipoproteinA #PCSK9 #Atherosclerosis #PrecisionMedicine

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Can AI truly overcome the high failure rates and long timelines in cardiovascular drug development—or are we underestimating the challenges?
https://t.co/szckl9hwe6
#CardioTwitter #AIinHealthcare #DrugDiscovery #PrecisionMedicine #ClinicalTrials

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Are we entering an era where “all-oral” combination lipid therapy can rival—or even replace—injectable strategies in high-risk patients?
https://t.co/NEdBWKMrPM
@gbiondizoccai
#CardioTwitter #Lipidology #ApoB #PreventiveCardiology #ASCVD

[Journal of Cardiovascular Pharmacology @JCVPOnline]

📢 Call for manuscripts for the special review series in Journal of Cardiovascular Pharmacology: Cardiac Aging and Biological Clocks.

We welcome high-quality reviews on circadian regulation, clock genes, aging clocks, and chronopharmacology with clear translational and clinical relevance.

Submit here: https://t.co/6JkpQPmtw0

#Cardiology #CircadianRhythms #Chronopharmacology #Aging #BiologicalClocks #CardioTwitter

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Can antibiotics quietly undermine one of our most trusted cardiovascular therapies?
https://t.co/qum1qabfvC
#CardioTwitter #Microbiome #Statins #Antibiotics #PrecisionMedicine

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Are we finally moving beyond symptom control to truly disease-modifying therapy in hypertrophic cardiomyopathy?
https://t.co/fRXVVqZF07
@DrMarikoHarper1

#CardioTwitter #HCM #Cardiomyopathy #PrecisionMedicine #HeartHealth

[Giuseppe Biondi-Zoccai @gbiondizoccai]

GRACE score for risk stratification and completeness of revascularization in older patients with myocardial infarction, by Luigi Spadafora, Marco Bernardi, Gianluca Campo, Simone Biscaglia, Francesco Versaci et al https://t.co/UmBYbszY4W

[Journal of Cardiovascular Pharmacology @JCVPOnline]

How should real-world muscle safety data shape our confidence in statin alternatives like bempedoic acid?
https://t.co/IwaHGtrMh7
#CardioTwitter #Lipidology #DrugSafety #Pharmacovigilance #RealWorldEvidence

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Could epigenetic modulation explain the cardioprotection seen with SGLT2 inhibitors?
https://t.co/M7DxYnHOhR
#CardioTwitter #SGLT2i #CardioEpigenetics #HeartFailure #TranslationalResearch

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Can intraoperative drug removal meaningfully change bleeding risk when urgent cardiac surgery can’t wait for antiplatelet washout?
https://t.co/BE5iPuZpWn

#CardioTwitter #CardiacSurgery #Pharmacokinetics #AntiplateletTherapy #MedicalDevices

[Journal of Cardiovascular Pharmacology @JCVPOnline]

As triple immune checkpoint regimens move closer to the clinic, are we ready to detect and manage their potential cardiotoxic risks early enough?
https://t.co/inXJy0Wfov
@istitutotumori

#CardioTwitter #CardioOncology #Immunotherapy #CancerResearch #TranslationalScience

[Journal of Cardiovascular Pharmacology @JCVPOnline]

Could a subtle shift in molecular structure unlock stronger vascular therapies?
https://t.co/9qLZLQcqZ6

#CardioTwitter #VascularBiology #NitricOxide #Pharmacology #TranslationalScience